cobas® SARS-CoV-2 Qualitative

Nucleic acid test for use on the cobas® 5800/6800/8800 Systems

IVD For in vitro diagnostic use.
<b>cobas</b><sup>®</sup> SARS-CoV-2 Qualitative
Robust, high-volume SARS-CoV-2 testing providing reliable results important for clinical decision-making

The cobas® SARS-CoV-2 Qualitative Test provides reliable and high-quality results for the improved management of COVID-19, in individuals suspected of COVID-19 by their healthcare provider. Healthcare professionals can use this test to assess if patients are at risk of developing the disease by this pathogen, which can contribute to severe respiratory distress, complications, and potential death.

Features and benefits of the cobas® SARS-CoV-2 Qualitative Test

The cobas®SARS-CoV-2 Qualitative Test is a single-well dual target assay, which includes both specific detection of SARS-CoV-2 and pan-Sarbecovirus detection for the Sarbecovirus subgenus family that includes SARS-CoV-2. The assay has a full-process negative control, positive control and internal control. Two kit sizes accommodating either 192 or 480 test reactions are available.

Claims include:

  • Use of nasal and nasopharyngeal swab sample types
  • Use of collection and transport media
    • cobas PCR Media Dual Swab Kit
    • cobas PCR Media Uni Swab Kit
    • cobas PCR Media Kit
    • Copan Universal Transport Media (UTM-RT)
    • BD™ Universal Viral Transport (UVT)
    • 0.9% Physiological Saline 

Please refer to the IFU for acceptable sample type and collection device combinations

Would you like to know more about the cobas® SARS-CoV-2 Qualitative Test?

Please submit your information in the following form to be contacted by a Roche representative with more details.

Form Successfully Submitted!
Thank you for your submission!



Robust performance achieved by targeting conserved regions within the ORF 1a/b and E genes

Simplicity & efficiency


Ready to use reagents and controls minimizing variability while simplifying the workflow and reducing risk of error



Full-process controls with negative, positive and internal controls

Hands-on Time


With only 3 manual interactions, up to 8 hours of walk-away time 
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2)

Since the start of COVID-19 pandemic, Roche is focused on bringing effective diagnostic solutions to healthcare communities worldwide in the fight against the disease.

As communities across the globe still need effective solutions for COVID-19, Roche continues to invest in diagnostics to ensure there are testing options available to healthcare communities and patients worldwide.

Test performance in individual samples*,a,b

View Full Table

Test performance in individual samples*,a,b

TARGET LoD (95% Probit)
SARS-CoV-2 200 IU/mLa
0.004 TCID50/mLb
pan-Sarbecovirus 102 IU/mLa
0.007 TCID50/mLb

cobas® SARS-CoV-2 Qualitative assay for use on the cobas 5800/6800/8800 Systems (192T & 480T) - Instructions for use

LoD determined with WHO International Standard for SARS-CoV-2 RNA (NIBSC code: 20/146)

one TCID50/mL is equal to 7,393 genome equivalents by ddPCR (per vendor’s Certificate of Analysis, USA-WA1/2020, infectious culture, Cat No NR-52281, Lot 70033175)

Nasopharyngeal SARS-CoV-2 97.2% 99.9%

Key Parameters

View Full Table

Key Parameters

Kit Configuration 192 and 480 test cassettes
Sample Type Nasal, nasopharyngeal
Transport media for nasal swabs

cobas® PCR Media Dual Swab Kit, cobas® PCR Media Uni Swab Kit, cobas® PCR Media Kit for nasal swabs, 0.9% Physiological Saline, Copan Universal Transport Medium (UTM-RT) or BD Universal Viral Transport (UVT)

Transport media for nasopharyngeal swab Copan Universal Transport Medium (UTM-RT) or BD Universal Viral Transport (UVT)
Min. amount of sample required Swab speciment types: 0.6 mL
Liquified saliva: 1.2 mL
Sample processing volume Swab specimen types: 0.4 mL
System software Runs with SW version 1.4 on cobas® 5800/6800/8800 Systems
Kit stability 90 days with 40 re-uses for 192 test cassette on cobas® 5800/6800/8800 Systems and 20 re-uses for 480 cassette on cobas® 5800/6800/8800 Systems
Intended Use

Intended Use

cobas® SARS-CoV-2 Qualitative for use on the cobas® 5800/6800/8800 Systems is a real-time RT-PCR test intended for the qualitative detection of nucleic acids from SARS-CoV-2 in nasal and nasopharyngeal specimens collected from symptomatic individuals suspected of COVID-19 by their healthcare provider.

Results are for the detection of SARS-CoV-2 RNA. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other pathogens.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Results are meant to be used in conjunction with clinical observations, patient history, recent exposures and epidemiological information, and laboratory data, in accordance with the guidelines provided by the relevant public health authorities. cobas® SARS-CoV-2 is intended for use by qualified clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and on the use of the cobas® 5800/6800/8800 Systems.

Registration Status

FDA 510(k) clearance


Detailed Specifications

Ordering Information

Compatible Instruments


    Technical Documents

    error errorMessage
    Sorry, we couldn't find the content you are looking for
    Please try again later